Drug Monograph
Full clinical overview, indications, dosage references & safety notes.
Overview
Dacarbazine (DTIC) is an injectable antineoplastic agent used in veterinary oncology primarily in dogs for the management of relapsed lymphoma, melanoma, and soft tissue sarcomas. It is administered intravenously as part of chemotherapy protocols and requires careful handling due to its hazardous nature.
This drug has a high emetogenic potential and commonly causes gastrointestinal adverse effects, which are often dose-limiting. Premedication with antiemetics is typically required to reduce acute vomiting. Dacarbazine can also cause bone marrow suppression, necessitating close monitoring during treatment.
Mechanism of Action (MOA): Dacarbazine is metabolized in the liver via cytochrome P450 enzymes to an active metabolite (MTIC). This metabolite generates reactive methyl groups that alkylate DNA, particularly at guanine bases, leading to inhibition of DNA replication and induction of DNA strand breaks. These effects ultimately result in cytotoxicity and tumor cell death.
Indications
Dacarbazine is used in dogs as a chemotherapeutic agent for the management of specific neoplastic conditions, particularly in cases where tumors are advanced, relapsed, or resistant to other treatments. It is typically incorporated into combination chemotherapy protocols rather than used as a sole agent.
- Relapsed lymphoma: Commonly used as part of rescue chemotherapy protocols in dogs with lymphoma that has recurred after initial treatment.
- Melanoma: Utilized in the management of malignant melanoma, especially in advanced or metastatic cases.
- Soft tissue sarcomas: May be included in treatment protocols for aggressive or non-resectable soft tissue sarcomas.
- Combination chemotherapy protocols: Frequently administered alongside other antineoplastic agents to enhance therapeutic efficacy in multi-drug regimens.
Dosage (Reference)
Dog
In dogs, dacarbazine is administered intravenously as part of chemotherapy protocols. Dosing is typically based on body surface area (m²) rather than body weight, and treatment is repeated in cycles depending on tumor response and bone marrow recovery.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| General chemotherapy protocol | IV | 200–250 mg/m² | q24h | Administer on days 1–5, then repeat cycle every 21–28 days. |
| Alternative protocol (high-dose infusion) | IV infusion | 800–1000 mg/m² | — | Administer over 4–8 hours; may repeat every 21 days if bone marrow has recovered. |
• Must be administered IV only; not for IM or SC use due to severe tissue injury risk.
• Always dilute before administration to reduce risk of irritation and extravasation.
• Use a well-placed IV catheter; extravasation can cause severe pain and tissue damage.
• Repeat dosing only after adequate bone marrow recovery (monitor CBC).
• Premedication with antiemetics is recommended due to high risk of acute vomiting.
Cat
Dacarbazine is not recommended for use in cats because it is unclear whether cats can adequately metabolize the drug. Safer alternative agents are generally preferred.
| Clinical use | Route | Dose | Frequency | Notes |
|---|---|---|---|---|
| All uses | — | Not recommended | — | Avoid use due to uncertain metabolism and safety concerns. |
• Not recommended due to lack of safety and metabolic data.
• Consider alternative chemotherapy agents with established use in cats.
• Use only if benefits clearly outweigh risks and with specialist supervision.
Warnings & Precautions
Dacarbazine is a potent chemotherapeutic agent that can cause serious, potentially life-threatening toxicity. Its use requires careful patient selection, strict administration technique, and close monitoring throughout treatment.
- Use in cats: Not recommended due to uncertain metabolism and lack of safety data; alternative agents are preferred.
- Hypersensitivity: Contraindicated in patients with a known history of hypersensitivity to dacarbazine.
- Bone marrow suppression: Use with caution in patients with preexisting bone marrow depression; monitor CBC regularly due to risk of anemia, neutropenia, and thrombocytopenia.
- Hepatic and renal dysfunction: Use cautiously in patients with liver or kidney impairment, as metabolism and excretion may be altered.
- Infection risk: Immunosuppressive effects may increase susceptibility to infections; avoid use in uncontrolled infections.
- Extravasation risk: Dacarbazine is a vesicant and can cause severe pain and extensive tissue damage if extravasation occurs; always administer via a properly placed IV catheter.
- Administration technique: Administer only via IV after a single, clean venipuncture attempt; never give IM or SC due to risk of severe tissue injury.
- Extravasation management: If extravasation occurs, stop infusion immediately and apply moderate dry heat to the area to promote drug dispersion and absorption.
- Hazardous drug handling: Classified as a hazardous drug; appropriate personal protective equipment (PPE) must be used to minimize exposure to veterinary staff.
- Pregnancy: Potentially teratogenic; avoid use in pregnant animals and confirm pregnancy status before administration.
- Monitoring requirements: Should only be used in settings where adequate monitoring and supportive care are available due to risk of severe toxicity.
Drug Interactions
Most clinically relevant interactions with dacarbazine are related to altered hepatic metabolism or additive bone marrow suppression. Careful monitoring and dose adjustments are required when combining dacarbazine with the following medications.
- CYP1A2 inducers (e.g., phenobarbital, rifampin): May increase the metabolism of dacarbazine, potentially reducing its therapeutic effect.
- CYP1A2 inhibitors (e.g., ciprofloxacin, mexiletine): May decrease metabolism, leading to increased drug exposure and risk of toxicity; consider therapy modification.
- Other myelosuppressive agents (e.g., antineoplastics, iron chelators): Increased risk of additive bone marrow suppression (anemia, neutropenia, thrombocytopenia); avoid combination when possible.
- Immunosuppressive drugs (e.g., cyclosporine, leflunomide, mycophenolate): Concurrent use may increase the risk of severe immunosuppression and infection.
- Vaccines (live and inactivated): May reduce vaccine efficacy and increase the risk of adverse effects; avoid vaccination during chemotherapy when possible.
Side Effects & Overdose
Side Effects
Adverse effects of dacarbazine in dogs are primarily dose-dependent and most commonly involve the gastrointestinal and hematopoietic systems. Careful monitoring is required, especially during the first few weeks after administration.
- Gastrointestinal toxicity: Very common and often dose-limiting; includes acute vomiting (within 24 hours), anorexia, and diarrhea. The drug is highly emetogenic, so premedication with antiemetics is recommended.
- Bone marrow suppression: Usually mild but may include anemia, neutropenia, and thrombocytopenia; thrombocytopenia is commonly observed 1–2 weeks after treatment.
- Severe hematologic toxicity: Rarely, life-threatening bone marrow suppression may occur with fatal consequences.
- Delayed toxicities: May include alopecia, hepatotoxicity, renal impairment, and photosensitivity reactions, although these are uncommon.
- Injection site reactions: As a vesicant, dacarbazine can cause pain, venous spasm, phlebitis, and tissue damage during IV administration.
- Hair coat changes: Some dogs may develop mild coat changes (e.g., dullness or texture changes); more noticeable alopecia may occur in breeds with continuously growing hair.
Overdose
Dacarbazine overdose can result in severe toxicity, particularly affecting the bone marrow and gastrointestinal system. There is no specific antidote, and management is primarily supportive.
- Severe bone marrow suppression: Marked neutropenia, thrombocytopenia, and anemia, increasing the risk of infection and bleeding.
- Severe gastrointestinal toxicity: Persistent vomiting, diarrhea, and potential dehydration.
- Systemic toxicity: May include hepatotoxicity and renal impairment in severe cases.
- Management: Supportive care is the mainstay of treatment, including fluid therapy, antiemetics, and close monitoring of hematologic parameters.
- Dose verification: Careful calculation and verification of doses are critical due to the narrow safety margin and potential for serious toxicity.
Key Notes
Practical clinical points to optimize the safe and effective use of dacarbazine in dogs during chemotherapy protocols:
- Protocol-based use: Rarely used as a single agent; most effective when incorporated into established multi-drug chemotherapy protocols.
- Body surface area dosing: Dosing is calculated using m² rather than body weight, which is standard for most chemotherapeutic agents.
- Cycle planning: Treatment is given in cycles (every 3–4 weeks), allowing time for patient recovery between doses.
- IV infusion considerations: High-dose protocols require slow infusion over several hours, so proper scheduling and monitoring during administration are essential.
- Dose adjustments: Future doses are often modified based on patient tolerance and hematologic recovery rather than fixed protocols.
- Monitoring timeline: Hematologic nadir typically occurs about 1–2 weeks after treatment, making this the critical period for follow-up evaluation.
- Handling precautions: As a cytotoxic drug, strict safety protocols should be followed during preparation and administration to minimize exposure risk.
- Client communication: Owners should be prepared for multiple treatment cycles and the need for regular monitoring visits during chemotherapy.
